Nosological classification (ICD-10)
Composition and release form
1 tablet contains methotrexate 2.5; 5 or 10 mg; in polypropylene bottles of 50 pcs., in the box one bottle.
1 ml solution for injection – 10 mg; Patients in the 1 or 5 ml, in the box 1 bottle.
1 ml of concentrate for the preparation of infusions – 100 mg; in vials of 5, 10 or 50 ml, in the box 1 bottle.
Is an antimetabolite antagonist of folic acid. Inhibits dihydrofolate reductase and inhibits the formation of tetrahydrofolate, which is involved in the biosynthesis of nucleic acids (transfer of single carbon fragments).
Suppresses mitosis, the growth of actively proliferating tissues (in
Indications drug Methotrexate-Ebeve
Acute lymphocytic leukemia, lymphogranulomatosis, head and neck cancer (squamous cell), lung, mammary gland; ovarian and testicular tumors; chorionepithelioma, soft tissue sarcoma, osteosarcoma, Ewing’s sarcoma; retinoblastoma; trophoblastic disease (mono- and combination therapy), autoimmune diseases, psoriasis (with refractoriness to other types of treatment).
Hypersensitivity, abnormal liver function and kidney function; bone marrow hypoplasia, leukopenia, thrombocytopenia, anemia; infectious diseases; ulcers in the mouth and gastrointestinal tract, postoperative conditions, pregnancy, breast-feeding.
Use during pregnancy and lactation
Contraindicated. At the time of treatment should stop breastfeeding.
Nausea, vomiting, difficulty swallowing, gingivitis, stomatitis, ulceration of the mucous membranes of the gastrointestinal tract, hemorrhages and other disorders of the digestive system and liver function, myelosuppression, immunosuppression, disorders of the genitourinary system (urination disorders, electrolyte balance, genital function); skin manifestations (erythema, alopecia, acne, etc.); headache, convulsions and other signs of CNS damage, allergic reactions.
Dosage and administration
Inside, before eating, without chewing, drinking water; in / m, in / in (bolus, infusion), in / a, intrathecal (subarachnoid). Doses are selected individually, depending on the disease, general condition and blood picture of the patient. Doses above 100 mg / m 2 of the body surface are administered only in / in a drip (the solution or concentrate is pre-diluted with 5% glucose solution to a level of 10 mg (500–1000 ml) and under the protection of calcium folinate. Intrathecal – 0.2–0.5 mg / kg (8–12 mg / m 2) every 2–3 days; after the symptoms disappear (or decrease), the interval between injections increases to 1 week, then to 1 month; prophylactically, every 6–8 weeks. With psoriasis, psoriatic arthritis, autoimmune diseases – 10–25 mg orally, weekly (it is also possible to administer intravenously or intramuscularly at the same dose); obaz – 2.5–5 mg, then the dose is increased to 7.5–25 mg / week (no more than 30 mg / week).
It is necessary to monitor the condition of the oral mucosa, liver and kidney function, peripheral blood.
Pongracz N. et al. The tolerability and toxicity of methotrexate in the treatment of malignant bone tumors. Translation of the German original in:
Storage conditions of the drug Methotrexate-Ebeve
Keep out of the reach of children.
The shelf life of the drug Methotrexate-Ebeve
Do not use after the expiration date printed on the package.